Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Delcath
Queensbury, New York, United States
- Ownership
- Public · DCTH
- Development stage
- Other
01
Overview
Delcath's HEPZATO KIT (melphalan/Hepatic Delivery System) is FDA approved and has demonstrated clinically meaningful tumor shrinkage with reduced systemic toxicity in metastatic uveal melanoma. Ongoing trials target other liver-dominant cancers, including metastatic breast and colorectal cancer. The pivotal FOCUS Phase 3 trial provided the efficacy basis for FDA approval[3][4].
- Therapeutic areas
- Oncology
- Modalities
- DeviceSmall molecule
- Industry
- Biotech
02
Partnerships
Synerx Pharma, LLC (melphalan supply)Mylan Teoranta (melphalan supply)
Beyond the preview
Go deeper on Delcath.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delcath.